MPA and MIA collaboration
7 November 2019
In a boost for melanoma patients across the country, Melanoma Patients Australia and Melanoma Institute Australia have announced a new multi-year agreement to provide enhanced support services for patients nationally. The agreement was announced at a Melanoma Information Forum held in Sydney, jointly hosted by both organisations. The forum detailed updates on treatments, surgery and strategies for living well and included expert advice from MIA Co-Medical Directors Professor Georgina Long and Professor Richard Scolyer.
The new MPA/MIA agreement will focus on:
- Introduction of a Tele Health Nurse Pilot Program to provide better access of services for melanoma patients
- Increased capacity and expertise of MPA’s Peer to Peer volunteer facilitators and volunteer support staff
- Enhanced face to face support groups within NSW and integration of these into MPA’s national support network
- Joint involvement in events including patient information sessions and MIA’s national Melanoma March campaign.
‘Both organisations look forward to partnering more closely to deliver enhanced support services to melanoma patients nationally,’ said Matthew Browne, CEO of Melanoma Institute Australia.
‘We are very excited and proud to be working with the incredible team at Melanoma Institute Australia,’ said Victoria Beedle, CEO of Melanoma Patients Australia. ‘MIA’s goal is zero deaths from melanoma achieved through research into new and exciting treatments for patients. With survival rates continuing to improve, the need for this collaboration to strengthen the Support Services available to our patients and families, is, thankfully, even greater. With this partnership we will achieve national synergies and strength from our collective efforts to raise awareness of melanoma in the community.’
The Australasian Melanoma Conference is bringing together some of the world's leading researchers and clinicians.
Best practice guidelines for melanoma care have gone digital with the first-ever online guidelines developed to adapt to the rapid change in clinical management.
Congratulations are in order for two of our talented researchers.
Professor Richard Scolyer will be sharing his expertise on melanoma pathology at the upcoming Australasian Melanoma Conference. Here he discusses what he'll be presenting on.
Researchers at MIA have established a High Risk Clinic to monitor people at very high risk of developing melanoma.
A generous donation has enabled a medical oncologist from Portugal to learn from the best in the world at MIA.
MIA is hosting a conference to bring together greats minds in melanoma research that will make a difference to the lives of melanoma patients
Meet Michelle, our Translational Research Officer whose role is to connect the clinics to the lab by ensuring patient blood and tissue samples are documented and carefully stored in our BioSpecimen Bank.
Dr James Wilmott says his Wildfire Award will help expand research into treatment options for people with mucosal melanoma, a rare but deadly form of skin cancer.
Following the recent hype around immunotherapies in cancer, CEO Carole Renouf shares the greatest story never told… resistance… and what MIA is doing to address it.
A/Prof Wargo discusses the research she will be presenting as a keynote speaker at the upcoming Australasian Melanoma Conference.
Dr James Wilmott has been awarded the Wildfire award at this year's Cancer Institute NSW's Premier Awards for Outstanding Cancer Research.
The community has responded generously to our recent appeal to fund a specialised nursing position in an exciting new clinical trial.
We have developed a unique clinical trial that will use existing drugs to target rare genes in melanoma patients.
Data presented at the recent ASCO Annual Meeting showcased advances in melanoma research, particularly long-term survival data.
We value your privacy and want you to be familiar with how we collect, use and disclose your information.
Melanoma Institute Australia has partnered with IBM Research in Australia to help further advance melanoma identification using cognitive technology.
CEO Carole Renouf chats to senior clinicians and researchers as part of our "4 Questions With..." short video series.
MIA's 'Stop the Spread' campaign has been shortlisted in the 2016 Cannes Lions International Festival of Creativity.